1. Home
  2. RVPH vs ASMB Comparison

RVPH vs ASMB Comparison

Compare RVPH & ASMB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • RVPH
  • ASMB
  • Stock Information
  • Founded
  • RVPH 2006
  • ASMB 2005
  • Country
  • RVPH United States
  • ASMB United States
  • Employees
  • RVPH N/A
  • ASMB 65
  • Industry
  • RVPH Biotechnology: Pharmaceutical Preparations
  • ASMB Biotechnology: Pharmaceutical Preparations
  • Sector
  • RVPH Health Care
  • ASMB Health Care
  • Exchange
  • RVPH Nasdaq
  • ASMB Nasdaq
  • Market Cap
  • RVPH 88.0M
  • ASMB 84.5M
  • IPO Year
  • RVPH N/A
  • ASMB 2010
  • Fundamental
  • Price
  • RVPH $2.09
  • ASMB $13.42
  • Analyst Decision
  • RVPH Strong Buy
  • ASMB Buy
  • Analyst Count
  • RVPH 5
  • ASMB 2
  • Target Price
  • RVPH $11.40
  • ASMB $35.00
  • AVG Volume (30 Days)
  • RVPH 1.8M
  • ASMB 22.6K
  • Earning Date
  • RVPH 11-14-2024
  • ASMB 03-27-2025
  • Dividend Yield
  • RVPH N/A
  • ASMB N/A
  • EPS Growth
  • RVPH N/A
  • ASMB N/A
  • EPS
  • RVPH N/A
  • ASMB N/A
  • Revenue
  • RVPH N/A
  • ASMB $28,326,000.00
  • Revenue This Year
  • RVPH N/A
  • ASMB $282.16
  • Revenue Next Year
  • RVPH N/A
  • ASMB N/A
  • P/E Ratio
  • RVPH N/A
  • ASMB N/A
  • Revenue Growth
  • RVPH N/A
  • ASMB N/A
  • 52 Week Low
  • RVPH $0.60
  • ASMB $9.84
  • 52 Week High
  • RVPH $4.83
  • ASMB $19.93
  • Technical
  • Relative Strength Index (RSI)
  • RVPH 60.41
  • ASMB 40.25
  • Support Level
  • RVPH $1.78
  • ASMB $13.60
  • Resistance Level
  • RVPH $2.15
  • ASMB $14.25
  • Average True Range (ATR)
  • RVPH 0.15
  • ASMB 0.58
  • MACD
  • RVPH 0.02
  • ASMB -0.05
  • Stochastic Oscillator
  • RVPH 88.30
  • ASMB 5.93

About RVPH Reviva Pharmaceuticals Holdings Inc.

Reviva Pharmaceuticals Holdings Inc is a late-stage pharmaceutical company that discovers, develops, and seeks to commercialize therapeutics for diseases. The current pipeline of the company focuses on the central nervous system, inflammatory, and cardiometabolic diseases. The company uses a chemical genomics-driven technology platform and proprietary chemistry to develop new medicines. The company's pipeline currently has two drug candidates, Brilaroxazine (RP5063) which is intended to treat multiple neuropsychiatric indications, including schizophrenia, bipolar disorder, depressive disorder, attention-deficit/hyperactivity disorder, behavioral and psychotic symptoms of dementia or Alzheimer's disease, and Parkinson's disease psychosis and its other drug candidate is RP1208.

About ASMB Assembly Biosciences Inc.

Assembly Biosciences Inc is a clinical-stage biotechnology company. It is advancing two innovative platform programs, a novel class of oral therapeutics for the treatment of hepatitis B virus (HBV) infection and novel class of oral synthetic live biotherapeutics, which are designed to restore health to a dysbiotic microbiome. The company's HBV-cure program is aimed at increasing the current low cure rate for patients with HBV and is pursuing multiple drug candidates that inhibit multiple steps of the HBV lifecycle. Assembly has discovered several novel core protein Allosteric Modulators, which are small molecules that directly target and allosterically modulate the HBV core protein. The majority of the revenue is generated from the HBV cure program.

Share on Social Networks: